FDA
-
-
-
-
-
-
-
Entera Bio Announces Collaboration with OPKO Biologics to Develop Oral Peptide Tablet Formulations for Obesity and Intestinal Malabsorption Syndromes
-
-
-
-
-
-
-
OPKO Health’s ModeX Therapeutics Enters into Exclusive Worldwide License and Collaboration Agreement with Merck to Develop Epstein-Barr Virus Vaccine Candidate
-
-
-
-
-
-
-
Pfizer and OPKO’s Once-Weekly NGENLA™ (somatrogon) Injection Receives Marketing Authorization in European Union for Treatment of Pediatric Growth Hormone Deficiency
-
-
-
-
-
-
-
OPKO Health Announces Topline Results from Phase 2 Trial Evaluating RAYALDEE to Treat Symptomatic COVID-19 Outpatients
-
-
-
-
-
-
-
OPKO Health (OPK) to Develop and Commercialize RAYALDEE® in Greater China with Nicoya Therapeutics
-
-
-
-
-
-
-
Pfizer (PFE) and OPKO (OPK) Announce EMA Accepts Marketing Application for Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency
-
-
-
-
-
-
-
Pfizer (PFE) Phase 3 Once-Weekly Investigational Study of Somatrogon to Treat Children with GHD Met its Primary Endpoint
-
251,370 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All